Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial.

Department of Neurology, University of Wisconsin, Madison 53792, USA.
JAMA The Journal of the American Medical Association (Impact Factor: 30.39). 01/1999; 280(21):1831-6.
Source: PubMed

ABSTRACT Pain is the most disturbing symptom of diabetic peripheral neuropathy. As many as 45% of patients with diabetes mellitus develop peripheral neuropathies.
To evaluate the effect of gabapentin monotherapy on pain associated with diabetic peripheral neuropathy.
Randomized, double-blind, placebo-controlled, 8-week trial conducted between July 1996 and March 1997.
Outpatient clinics at 20 sites.
The 165 patients enrolled had a 1- to 5-year history of pain attributed to diabetic neuropathy and a minimum 40-mm pain score on the Short-Form McGill Pain Questionnaire visual analogue scale.
Gabapentin (titrated from 900 to 3600 mg/d or maximum tolerated dosage) or placebo.
The primary efficacy measure was daily pain severity as measured on an 11-point Likert scale (0, no pain; 10, worst possible pain). Secondary measures included sleep interference scores, the Short-Form McGill Pain Questionnaire scores, Patient Global Impression of Change and Clinical Global Impression of Change, the Short Form-36 Quality of Life Questionnaire scores, and the Profile of Mood States results.
Eighty-four patients received gabapentin and 70 (83%) completed the study; 81 received placebo and 65 (80%) completed the study. By intent-to-treat analysis, gabapentin-treated patients' mean daily pain score at the study end point (baseline, 6.4; end point, 3.9; n = 82) was significantly lower (P<.001) compared with the placebo-treated patients' end-point score (baseline, 6.5; end point, 5.1; n = 80). All secondary outcome measures of pain were significantly better in the gabapentin group than in the placebo group. Additional statistically significant differences favoring gabapentin treatment were observed in measures of quality of life (Short Form-36 Quality of Life Questionnaire and Profile of Mood States). Adverse events experienced significantly more frequently in the gabapentin group were dizziness (20 [24%] in the gabapentin group vs 4 [4.9%] in the control group; P<.001) and somnolence (19 [23%] in the gabapentin group vs 5 [6%] in the control group; P = .003). Confusion was also more frequent in the gabapentin group (7 [8%] vs 1 [1.2%]; P = .06).
Gabapentin monotherapy appears to be efficacious for the treatment of pain and sleep interference associated with diabetic peripheral neuropathy and exhibits positive effects on mood and quality of life.

1 Follower
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective: The aim of this study is to estimate the pharmaceutical equivalence of 3 different brands of gabapentin capsules available in Karachi, Pakistan. Gabapentin (1-(amino methyl) cyclohexane acetic acid) is a novel anticonvulsant drug having pain-relieving effect in diabetic neuropathy, postherpetic neuralgia and neuropathic pain. Gabapentin has an effect on the nociceptive process by binding to the α2δ subunit of voltage dependent calcium channels. Method: The three different brands of gabapentin capsules (100 mg) randomly were selected and evaluated for quality control (QC) parameters which include weight variation, disintegration and dissolution tests specified by British Pharmacopoeia and United state Pharmacopoeia. Results: The values of weight of all brands of gabapentin complied with USP limits. The disintegration time of all brands of gabapentin was within 15 minutes thus collate with the USP specification. All brands of gabapentin revealed more than 80% release of drug within 20 minutes. Conclusion: The three brands of gabapentin capsules available in Karachi meet the USP specification for quality control analysis.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: One of the most frequent problems in medical care is the management of patient presenting with chronic pain. Neuropathic pain is related to the injury or disorders affecting peripheral and central nervous systems and is resistant to over-the-counter analgesics and conventional treatment methods. The estimated prevalence for patients presenting classical symptoms of neuropathic pain is eventually reported to be 6%–8%. Several mechanisms have been considered and proposed for this disorder. The involvement of small and large sensory fibers as well as motor fibers is a reason for the presence of neuropathic pain. In addition to the lifestyle modification, a number of different therapeutic approaches and treatment protocols have been applied to control the neuropathic pain. However, management is still unsatisfactory. Comorbidities such as depression, anxiety, and sleep disorders are associated with this disorder and should be previously considered and eliminated. Analgesics, tricyclic antidepressants, anticonvulsant, serotonin– norepinephrine reuptake inhibitors, and local anesthetic agent as well as opioid analgesics and herbal medicaments such as capsaicin are known treatment lines for the management of neuropathic pain. Regarding the unsuccessfulness of single therapy, poly-pharmacy or combination therapy of two or more agents with synergistic mechanisms and different modes of action seems necessary.
    01/2015; 5(3). DOI:10.5455/njppp.2015.5.2812201418
  • [Show abstract] [Hide abstract]
    ABSTRACT: The amino acid [1-(aminomethyl)cyclohexyl]acetic acid was reacted with 2-hydroxynaphthaldehyde to produce the Schiff base ligand [1-({[(Z)-(2-hydroxynaphthalen-1-yl)methylidene]amino}methyl)cyclohexyl]acetic acid (H-HMAC) which was fully characterized spectroscopically and by single crystal diffraction. It was reacted with metal ions to produce compounds with composition [M(HMAC)2] [M = Co(II), Ni(II), Cu(II) and Zn(II)], which were characterized spectroscopically, with distorted tetragonal geometries assigned based on spectroscopic and B3LYP theoretical studies. All synthesized compounds were studied for their thermal stabilities under static air. The coordination compounds were also screened for their free radical scavenging properties using DPPH free radicals and xanthine oxidase inhibitory activities. Only the zinc complex was found to be an inhibitor of the enzymatic activity with IC50 = 0.7 ± 0.01 μM ± SEM better than the standard reference drug used. The inhibitory activity was structurally rationalized by carrying out molecular modeling studies using the auto dock program.
    Inorganica Chimica Acta 03/2015; 428:117. DOI:10.1016/j.ica.2015.01.021 · 2.04 Impact Factor

Full-text (2 Sources)

Available from
May 16, 2014